Drug Profile
Research programme: CCR4 antagonists - AstraZeneca
Alternative Names: AZD-1678Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Pyrazines; Small molecules; Sulfonamides
- Mechanism of Action CCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-asthma in United Kingdom
- 20 Aug 2009 Preclinical trials in Allergic asthma in United Kingdom (unspecified route)